Our Story

Tessa Therapeutics is founded on over three decades of research and development by our Scientific Co-Founder, Dr. Malcolm K Brenner, and his team at Baylor College of Medicine. Their research has shown that the body’s anti-viral immune response can be harnessed as a potent therapy for cancer treatment.

Learn More

Our Science

Our core platform technology uses a specific subset of immune cells known as Virus-Specific T cells (VSTs) which have shown early efficacy and strong safety profiles against solid tumors in clinical trials. We employ our understanding of the body’s anti-viral immune response to rationally design the next generation of cancer treatments.

Learn More

Our Pipeline

We have an advanced clinical pipeline of autologous and allogeneic therapies that combine VSTs with other immune-oncology approaches to target multiple tumor indications.

Learn More

Our Operations

We have successfully delivered cell therapies to patients in 30 clinical sites across Asia and North America, enabled by a global vein-to-vein operations and strong clinical trial network.

Learn More
null

Our Story

null

Our Science

null

Our Pipeline

null

Our Operations

Feature News

Tessa at a Glance

200+ employees

Learn More >>

5 Pipeline Assets

Learn More >>

Global Operations & Clinical Trial Network

Learn More >>

6 Strategic Partnerships

Learn More >>

Process Development Facility

Learn More >>

Upcoming cGMP Manufacturing Facility

Learn More >>

Tessa on Twitter

4 weeks ago
Our CSO, John Connolly @hotirishmonkey speaks with Dr Jonathan Maltzman @StanfordMed about harnessing Regulatory T Cells and inhibiting them to fight cancer and other viral illnesses. Watch the interview: https://t.co/pk2uQj6k8B #immunotherapy #celltherapy #solvecancer https://t.co/mHIMRC1sss
2 months ago
Dr Göran Ando, who joined Tessa’s Board of Directors last April, recently shared his views on the potential of #celltherapy and the key ingredients needed to successfully translate early research efforts into patient treatments: https://t.co/dgntjqQ5Ub

Tessa’s Media Channel

In this second interview, our CSO, John Connolly speaks to Dr Jeffrey Bluestone, who is the President and CEO at the Parker Institute for Cancer Immunotherapy. Dr Bluestone discusses the impact of cell immunotherapy in changing the field of pharmaceutical drug development and the all-important role of cross-industry collaboration in the future success of cell therapies.